Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study.

@article{Durie1990PrognosticVO,
  title={Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study.},
  author={Brian G. M. Durie and Donna Stock-Novack and Sydney Salmon and Patrick Finley and Jean Beckord and John C Crowley and Charles Arthur Coltman},
  journal={Blood},
  year={1990},
  volume={75 4},
  pages={823-30}
}
Six hundred twelve eligible, previously untreated patients with active multiple myeloma and at least some data available for analysis were entered into a randomized trial (Southwest Oncology Group [SWOG] Phase III myeloma study 8229/30), in which the prognostic significance of pretreatment serum beta 2 microglobulin levels was evaluated. Because there was no statistically significant survival difference between the alternating and syncopating VMCP/VBAP regimens, it was possible to evaluate… CONTINUE READING